anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The management and prognosis of patients with glioma is highly dependent on the tumour grade according to the new 2016 classification of the World Health Organization (WHO), which incorporates molecular characteristics. Standard magnetic resonance imaging (MRI) enhanced by contrast is the basis of imaging primary brain tumours including gliomas. Nevertheless MRI specificity to type glioma is limited. Recently, positron emission tomography (PET) molecular imaging using radiolabeled amino acids or their analogues has been recommended by the Neuro-Oncology Response Assessment (RANO) working group for differential diagnosis of brain lesions, non-invasive classification of glial tumours, prognostic value, tumour delineation, stereotactic biopsy radiotherapy planification and treatments follow-up, to provide additional informations beyond MRI on biological processes such as cell proliferation, membrane biosynthesis, glucose consumption and absorption of amino acid analogues. Among the radiotracers used in PET, radiolabeled amino acids or their analogues are increasingly used in clinical routine for glioma imaging. Although most previous PET studies focused on brain gliomas used L-\[methyl- 11 C\] -methionine (11C-MET), the fluorinated amino acid analogue O - (2-\[ 18 F\] fluoroethyl) -L-tyrosine (18F-FET) appeared to be a favorable marker for clinical routine due to his longer half-life than Carbone 11. Recent european guidelines attempt to provide some guidance on the performance and interpretation of molecular imaging. The authors recommend a static (20-40 mn after injection (Pi)) or dynamic PET acquisition (40-50 mn from injection). A visual analysis can be completed by a quantitative analysis which consists to measure mean and maximal tumour activity uptake values (SUVmean and SUVmax) and their respective tumour to background ratios (TBRmean and TBRmax). Although the mean physiological brain activity uptake is well defined, the measurement of mean glioma activity uptake is less clear. Indeed, TBRmean depends on the delineation of the tumour ROI and/or VOI. Most often previously, VOI was determined by a 3D contouring process using a tumour-to-brain ratio of at least 1.6 at the beginning of the scan, threshold defined on a brain gliomas biopsy-controlled study. Moreover, Albert et al. emphasized the interest of early TBRmax.To our knowledge, none study evaluated others parameters as SUVmax, SUVmean and TBRmean in early period. In this context, the aim of this study was to compare quantitative and qualitative PET parameters between Low Grade Glioma and High Grade Glioma.
Regarding the therapy of cerebral parenchyma tumors, the extent of resection (EOR) has a significant impact on the prognosis. However, total resection is not possible in up to 65% of cases because these tumors frequently infiltrate eloquent areas such as language or motor centers. Consequently, an optimal oncologic result from the surgical perspective cannot be achieved in a considerable large amount of patients. One possible solution is based on the tumor-induced shift of functional areas, which can move away from their original localization. Earlier studies already described the resection of glioma residuals during a second surgery after plastic reorganization has taken place. The authors complained that this reorganization is not detectable without surgery. Navigated transcranial magnetic stimulation (nTMS) was developed for the noninvasive localization of motor and language areas, which enables us to detect the spatial shift of cortical motor and language functions in tumor patients. Recent publications were already able to demonstrate that the individual and exact localization of the motor cortex leads to an increased EOR and prolongs the progression-free survival (PFS). Therefore, the current project intends to take advantage of this plastic reorganization for EOR optimization in cerebral parenchyma tumors. In this context, nTMS is supposed to also induce this plasticity within the frame of a repetitive stimulation protocol (rTMS). Besides other therapeutic applications, rTMS also showed a positive effect on the improvement of aphasia as well as motor recovery in patients after stroke, even in randomized multicenter studies, by inducing plastic reorganization. Moreover, rather than waiting for tumor-induced plastic reorganization, the investigators also aim to use the potential of rTMS for spatial plastic reorganization of functional areas adjacent to intracerebral parenchymal tumors to move functionally eloquent brain regions away from the planned resection cavity.
The present invention relates to a use of alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis. The use is suitable for various type of psoriasis by utilizing photodynamic therapy. The photosensitizer is used to treat psoriasis by utilizing laser wave length of 670nm, with high light sensitivity, fast photobleaching, short time needed in protection from light, and avoiding potential toxic and side-effect of photochemistry therapy by using ultraviolet irradiation. The preparation used in the use of α-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis includes solution, cream, nanomicelle, microsphere etc, and mode of administration can be systemic or topical administration. The practicability of treating psoriasis by photodynamic therapy has been validated on cell and animal model. The use achieves perfect effect.
Methods and compositions are disclosed for producing air-activated, i.e., oxygen (O 2 ) activated, disinfectant-sterilent solutions. Solutions containing a haloperoxidase (i.e., a halide:hydrogen peroxide (H 2  O 2 ) oxidoreductase, such as myeloperoxidase, eosinophil peroxidase or lactoperoxidase) plus a halide or combination of halides (i.e., chloride, bromide and/or iodide), an oxidase (i.e., a substrate: O 2  oxidoreductase) capable of generating H 2  O 2 , and a substrate specific for that oxidase, are separately prepared under aerobic conditions, but all of the component solutions are made anaerobic prior to final combination and mixing. The anaerobic formulations are dispensed into containers capable of maintaining the anaerobic condition (e.g., pressurized canisters). Dispensing the solution at the time of use exposes the formulation to air (i.e., O 2 ) which activates its disinfectant-sterilent properties. O 2  is the rate limiting component for oxidase generation of H 2  O 2 . Under aerobic conditions the oxidase catalyzes the oxidation of its substrate and the reduction of O 2  to generate H 2  O 2 . In turn, H 2  O 2  serves as substrate for haloperoxidase which catalyzes the oxidation of halide to hypohalous acid. Hypohalous acid reacts with an additional H 2  O 2  to generate singlet molecular oxygen ( 1  O 2 ). Hypohalous acid (e.g., hypochlorous acid) and especially  1  O 2  are potent microbicidal agents. Both haloperoxidase generation of hypohalous acid and its reactive consumption to yield  1  O 2  are dependent on the availability of H 2  O 2 . A high rate of H 2  O 2  generation does not result in the accumulation of hypohalous acid, but instead results in a high rate of  1  O 2  production. The microbicidal capacity and toxicity of  1  O 2  are limited by the half-life of this metastable electronically excited reactant, and as such, disinfectant-sterilent activity is temporally defined by and confined to the dynamics of oxidant generation.
Pharmaceutical compositions comprising: 65-85% w/w ibuprofen; 15-30% w/w coating material coating the ibuprofen; and 3-15% w/w matrix surrounding the coated ibuprofen. The coating material preferably comprises a wax such as carnauba wax, candelilla wax, or synthetic wax. The coating material may further comprise a second coating material comprising silica. The matrix preferably comprises a matrix former such as gelatin, and a structure former such as mannitol. Preferably the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25°C and at least 60 % relative humidity. The pharmaceutical composition may be used in methods of treating patients.
Those assigned to the Powdered Meal Replacement group will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
PURPOSE:To obtain the novel derivative, excellent in UV-A absorptivity, usability, further UV rays protecting effects, water resistance and feeling of use and useful as an UV rays absorber and a skin external preparation. CONSTITUTION:This 1,3-butadienyl ketone derivative is expressed by formula I [R1 is H, 1-8C alkyl or alkoxy; R2 is H or 1-4C alkyl; R3 is 1-8C alkyl or aryl expressed by formula II (R4 is H, OH or 1-8C alkoxy)], e.g. (4-phenyl-1,3- butadienyl t-butyl ketone. The derivative expressed by formula I is obtained by subjecting a substituted cinnamaldehyde and various methyl ketone derivatives to condensation reaction in the presence of an alkaline catalyst or an acidic catalyst (e.g. pyridine, NaOH or hydrochloric acid) in a solvent (e.g. benzene or toluene) at a temperature between 0 deg.C and the boiling point of the solvent.
There have been postmarketing reports of serious hypersensitivity reactions in patients treated with saxagliptin. These reactions include anaphylactic reactions, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with saxagliptin, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue QTERN, treat per standard of care, and monitor until signs and symptoms are resolved. Assess for other potential causes for the event. Institute alternative treatment for diabetes.

Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with saxagliptin.
For restoration of M1 group, capsule activation will be performed through loading of the KetacTM Universal AplicapTM GIC capsule into its activator keeping the applicator nozzle closed, using the ball of my hand to depress the activator lever firmly as far as it will go and hold it down for 2 to 4 seconds. Then the capsule will be mixed in a high frequency mixing device for 8 seconds. The mixed capsule will be immediately removed from the mixer and loaded into the AplicapTM Applier then application nozzle will be opened to extrude the mixture directly into the preparation as a single bulk within 1:40 minute. The preliminary contour will be done using a ball burnisher.
Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
DESIGN NARRATIVE:

There were two specific aims. The first was to test the hypothesis that controlled physical training (PT) reduced blood pressure, at rest and in reaction to forehead cold and exercise stressors, in 8-9 year olds who were high in both blood pressure and body fatness. Subjects were divided equally on gender and blood pressure and body fatness. Subjects were divided equally on gender and ethnicity (black/white). Both resting and reactive blood pressure were correlated with left ventricular mass and were predictive of future essential hypertension. The underlying hemodynamic regulators of blood pressure, cardiac output and the total peripheral resistance, were measured with impedance cardiography to explore hemodynamic mechanisms through which training had a favorable influence on blood pressure and left ventricular mass.

The second aim tested the hypothesis that physical training reduced percent body fat, as measured with dual energy x-ray absorptiometry (DEXA). Children above the 70th percentile in both blood pressure and fatness were randomly assigned, within ethnicity and gender, to a physical training or waiting list control group. After the physical training group underwent four months of training, all subjects were retested and these data were used to test the primary hypotheses. The initial control subjects then performed four months of physical training, after which they were retested. The data from this second phase were added to the data of the initial physical training group to explore interactions of training with gender and ethnicity. The initial physical training group was brought back four months after cessation of training to see if the changes elicited by the training were reversible. To document the stimulation provided by the training, heart rate was monitored during training sessions. To observe the time course of changes between the full lab testing sessions, skinfolds and resting blood pressure were measured monthly. Diet and free living physical activity were assessed to help explain changes in body composition. Aerobic fitness was measured with treadmill tests of maximal oxygen consumption.
Bleomycin 1000 iu/ ml. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
PROBLEM TO BE SOLVED: To obtain an elastomer silicone polyether composition having a crosslinked three-dimensionally gelled network containing the below-described active component and oil by reacting an ≡SiH-containing polysiloxane, a monoalkenylpolyether, an active component containing a constituent present in a drug product, and an α,ω-unsaturated hydrocarbon in the presence of a platinum catalyst and an oil. SOLUTION: This composition has a useful value in the field of personal care, e.g. as a carrier for a sweat inhibitor, etc. For example, the ≡SiH- containing polysiloxyane is a copolymer corresponding to formula I: Me3SiO(Me2 SiO)77(MeHSiO)20SiMe3. Monoalkenylpolyether is the one represented by formula II (wherein T is H, 1-10C alkyl, or the like). 1,5-Hexadiene is used as the α,ω- unsaturted hydrocarbon. The oil is a cyclic siloxane, the catalyst is a Karstedt catalyst, and the active component is vitamin E, female hormone or the like.
After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria which include screening hematology, chemistry and erythrocyte sedimentation rate (ESR) laboratory evaluations. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine manufactured by bioCSL administered at different dosages (7.5 or 15 mcg of HA/0.5 mL dose) given with or without AS03 or MF59 adjuvants manufactured by GlaxoSmithKline Biologicals and Novartis Vaccines and Diagnostics, respectively. The primary objectives of this study is to assess 1) the safety and reactogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine and 2) the serum hemagglutination inhibition (HAI) and neutralizing (Neut) antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (7.5 or 15 mcg of HA/0.5 mL dose) given with or without AS03 or MF59 approximately 21 days apart. The secondary objectives of this study are to 1) assess study vaccine-related unsolicited non-serious adverse events following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine, 2) assess medically attended adverse events (MAAEs) including new-onset chronic medical conditions and immune-mediated or auto-inflammatory adverse events of special interest following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine, and 3) assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of one dose administered intramuscularly at different dosages (7.5 or 15 mcg of HA/0.5 mL dose) given with or without AS03 or MF59. This study will span approximately 24 months. Subject participation duration will span approximately 13 months.
Method for the prepn. of antimicrobial agents contng. as the active ingredients a synergistic mixture of:- (a) a vinyl sulphonic acid phenyl ester of the general formula (I) R2, R3, R4, R5 and R6 are hydrogen, chlorine, bromine, iodine, fluorine, SCN group, nitro group, aliphatic group with 1 to 4C atoms, which may be optionally substd., or a phenyl group. and (B) a nitro aliphatic alcohol with the general formula (II) where R = hydrogen, or methyl or phenyl group which may be optionally substd. with halogen or nitro groups X = hydrogen, bromine, hydroxymethyl group B = hydrogen, methylethyl or hydroxymethyl group or (c) the phenyl carbamic acid ester of a nitro alcohol with the general formula (III) Y = chlorine or nitro group n = 0, 1 or 2 R, X and B are as above but in addition B may be a phenyl carbamic acid ester group of the formula (IV) in which Y, R and n are as above. The mixtures are active as anti-microbials, as anti-bacterials and against yeasts.
The invention relates to a traditional Chinese medicine formula for treating chyluria. The traditional Chinese medicine comprises the following components in parts by weight: 10-15 parts of largehead atractylodes rhizome, 12-18 parts of sevenlobed yam rhizome, 8-12 parts of amur corktree bark, 8-12 parts of grassleaf sweelflag rhizome, 12-18 parts of glabrous greenbrier rhizome, 18-22 parts of plantain seed, 8-12 parts of depositum urinae praeparatum, 8-12 parts of peach seed, 8-12 parts of corn stigma and 2 parts of aquatic grass; and the components of the traditional Chinese medicine are snatched according to the content and decocted for administration. The traditional Chinese medicine has certain advantages on the treatment of the chyluria. In the invention, a fixed prescription is applied for treating patients with the chyluria; and if symptoms of the patients change, 2-3 types of traditional Chinese medicines can be added on the basis of the fixed prescription for carrying out effective treatment on the patients. Compared with the traditional Chinese medicine dialectical method, the technical method has the following great advantages: 1) the prescription is relatively fixed, easy to grasp, good in quality control and simple and convenient for being used by the patients; and 2) the traditional Chinese medicine formula is not separated from one of cores of the traditional Chinese medicine-diagnosis and treatment, realizes individualized treatment and is conductive to improving the clinical efficacy. By applying the technology for treatment, the effective rate of the patients can be 90.7%, the cure rate is 81.6%, and the five-year recurrence rate is less than 20%.
The invention relates to methods for diagnosing liver cancer, in particular intrahepatic cholangiocarcinoma (ICC) or hepatoblastoma, predicting the survival time and methods for the treatment of liver cancer, in particular intrahepatic cholangiocarcinoma (ICC) or hepatoblastoma. The inventors investigated the invasiveness of liver cancer and the formation of unfiltered ducts in hepatic parenchyma (intrahepatic cholangiocarcinoma: ICC, hepatoblastoma). The inventors also investigated the invasive tissue transformation associated to abnormal expression in liver of cholangio/hepato bipotent progenitor markers. PIK3CD expression was found significantly correlated to progenitor markers such as CD44, KRT19, PROM1 and THY1 in liver cancers and mutated, especially in PI3Ka domain suggested to be implicate in substrate presentation. PIK3CD mutations are significantly associated with a lower overall survival. The inventors performed overexpression of PIK3CD in HUH7 3D cell culture and its influenced lumen and tubular formation of this cell model. Transcriptome analysis in triplicate was performed on this cell model with WT and PIK3CD knock-in conditions. 85 genes from HUH7 KI-PIK3CD expression profile were found predictive for ICC, hepatoblastoma and cholangiocarcinoma (CC) subclass of liver cancer. Thus, the invention relates to methods for diagnosing liver cancer, in particular intrahepatic cholangiocarcinoma (ICC) or hepatoblastoma, predicting survival time and PI3KCD inhibitor for use in the treatment of liver cancer, in particular intrahepatic cholangiocarcinoma (ICC) or hepatoblastoma.
BACKGROUND: We report the first case of cimetidine as an alternative adjuvant therapy in a pregnant woman with recurrent respiratory papillomatosis (RRP). A 40 year old woman at 19 week gestation presented with progressive hoarseness and shortness of breath for 1 month. Flexible nasopharyngolaryngoscopy revealed multiple papillomatous lesions over both vocal cords and subglottic area obstructing 60% of her airway. She had previously been diagnosed with juvenile onset RRP at the age of 5 and underwent endoscopic clearance regularly every 6 months.
METHOD: The patient was started on a trial of oral cimetidine at a dose of 30 mg/kg and responded well, eventually requiring endoscopic excision only after 2 years. Subsequently, she underwent in vitro fertilisation treatment and stopped taking her cimetidine. After undergoing endoscopic clearance of her papillomata under general anaesthesia, she restarted on cimetidine during her 2nd and 3rd trimester.
RESULTS: Ensuing follow-up demonstrated stable minimal papillomata lesions on her right inferior surface of her vocal cord with no recurrence on her left vocal cord and subglottic area.
CONCLUSION: Cimetidine is generally safe and not known to be associated with any major teratogenic risks during pregnancy. RRP is postulated to worsen in pregnant women due to the increase in oestrogen levels during pregnancy. Hence, adjuvant therapy was imperative for our patient to reduce recurrent papillomata formation during her pregnancy. Larger scale studies are warranted to assess the use of long-term high-dose cimetidine in terms of efficacy and safety in pregnancy.
Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.